Alnylam Pharmaceuticals (NASDAQ:ALNY) Posts Earnings Results, Beats Estimates By $0.23 EPS

Alnylam Pharmaceuticals (NASDAQ:ALNY) issued its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.75) by $0.23, Briefing.com reports. The company had revenue of $494.33 million for the quarter, compared to analyst estimates of $428.01 million. During the same quarter last year, the company earned ($1.40) EPS. The firm’s quarterly revenue was up 54.8% on a year-over-year basis.

Alnylam Pharmaceuticals Price Performance

ALNY traded up $2.02 during mid-day trading on Friday, hitting $152.33. The stock had a trading volume of 452,157 shares, compared to its average volume of 763,489. The stock’s fifty day simple moving average is $149.76 and its 200-day simple moving average is $165.25. The firm has a market capitalization of $19.19 billion, a price-to-earnings ratio of -42.22 and a beta of 0.41. Alnylam Pharmaceuticals has a 1-year low of $141.98 and a 1-year high of $218.88.

Analyst Ratings Changes

A number of brokerages have recently issued reports on ALNY. The Goldman Sachs Group lowered shares of Alnylam Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $230.00 to $173.00 in a research report on Friday, February 16th. Citigroup lowered their target price on Alnylam Pharmaceuticals from $237.00 to $227.00 and set a “buy” rating for the company in a research note on Friday, February 16th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $235.00 price target on shares of Alnylam Pharmaceuticals in a research note on Tuesday, February 20th. StockNews.com upgraded Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Monday. Finally, Wells Fargo & Company dropped their price objective on Alnylam Pharmaceuticals from $171.00 to $161.00 and set an “equal weight” rating for the company in a report on Friday, February 16th. Seven analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $215.88.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.